Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis

Neda Dadgar,Christopher Sherry,Jenna Zimmerman,Hyun Park,Catherine Lewis,Albert Donnenberg,Ali H. Zaidi,Yong Fan,Kunhong Xiao,David Bartlett,Vera Donnenberg,Patrick L. Wagner
DOI: https://doi.org/10.1186/s12967-024-05205-8
IF: 8.44
2024-04-30
Journal of Translational Medicine
Abstract:Abstract Peritoneal carcinomatosis (PC) is a complex manifestation of abdominal cancers, with a poor prognosis and limited treatment options. Recent work identifying high concentrations of the cytokine interleukin-6 (IL-6) and its soluble receptor (sIL-6-Rα) in the peritoneal cavity of patients with PC has highlighted this pathway as an emerging potential therapeutic target. This review article provides a comprehensive overview of the current understanding of the potential role of IL-6 in the development and progression of PC. We discuss mechansims by which the IL-6 pathway may contribute to peritoneal tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and immune response modulation. Finally, we review the prospects for targeting the IL-6 pathway in the treatment of PC, focusing on common sites of origin, including ovarian, gastric, pancreatic, colorectal and appendiceal cancer, and mesothelioma.
medicine, research & experimental
What problem does this paper attempt to address?